A Global Registration Trial of AC-203 for the Treatment of Epidermolysis Bullosa
Latest Information Update: 25 Jan 2019
At a glance
- Drugs Diacerein (Primary)
- Indications Epidermolysis bullosa
- Focus Registrational; Therapeutic Use
Most Recent Events
- 25 Jan 2019 New trial record
- 22 Jan 2019 According to a TWi Biotechnology media release, this global registration trial will be conducted in partnership with Castle Creek Pharma (CCP).